PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Edwards Lifesciences Corporation (EW)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US28176E1082

CUSIP

28176E108

Sector

Healthcare

IPO Date

Mar 27, 2000

Highlights

Market Cap

$39.34B

EPS (TTM)

$2.55

PE Ratio

25.81

PEG Ratio

6.08

Total Revenue (TTM)

$5.87B

Gross Profit (TTM)

$4.57B

EBITDA (TTM)

$1.70B

Year Range

$58.93 - $96.12

Target Price

$75.12

Short %

1.38%

Short Ratio

1.15

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons:
EW vs. BAX EW vs. SYK EW vs. NVNO EW vs. SPY EW vs. MCK EW vs. IHI EW vs. DHR EW vs. LLY EW vs. SCHG EW vs. VOO
Popular comparisons:
EW vs. BAX EW vs. SYK EW vs. NVNO EW vs. SPY EW vs. MCK EW vs. IHI EW vs. DHR EW vs. LLY EW vs. SCHG EW vs. VOO

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Edwards Lifesciences Corporation, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


0.00%1,000.00%2,000.00%3,000.00%4,000.00%5,000.00%6,000.00%7,000.00%JuneJulyAugustSeptemberOctoberNovember
4,828.00%
285.25%
EW (Edwards Lifesciences Corporation)
Benchmark (^GSPC)

Returns By Period

Edwards Lifesciences Corporation had a return of -11.13% year-to-date (YTD) and 1.29% in the last 12 months. Over the past 10 years, Edwards Lifesciences Corporation had an annualized return of 12.52%, outperforming the S&P 500 benchmark which had an annualized return of 11.16%.


EW

YTD

-11.13%

1M

-3.57%

6M

-23.98%

1Y

1.29%

5Y (annualized)

-3.56%

10Y (annualized)

12.52%

^GSPC (Benchmark)

YTD

23.62%

1M

0.54%

6M

11.19%

1Y

30.63%

5Y (annualized)

13.61%

10Y (annualized)

11.16%

Monthly Returns

The table below presents the monthly returns of EW, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
20242.91%8.16%12.60%-11.40%2.62%6.31%-31.74%10.96%-5.67%1.55%-11.13%
20232.80%4.88%2.85%6.35%-4.26%11.99%-13.00%-6.82%-9.40%-8.03%6.26%12.61%2.20%
2022-15.71%2.90%4.76%-10.14%-4.66%-5.71%5.73%-10.38%-8.29%-12.34%6.65%-3.42%-42.41%
2021-9.48%0.63%0.65%14.20%0.40%8.00%8.40%4.37%-3.39%5.84%-10.44%20.73%42.00%
2020-5.76%-6.83%-7.92%15.31%3.32%-7.74%13.46%9.48%-7.01%-10.19%17.02%8.75%17.32%
201911.26%-0.66%13.02%-7.98%-3.05%8.22%15.22%4.22%-0.87%8.40%2.75%-4.76%52.31%
201812.31%5.60%4.38%-8.72%7.81%6.02%-2.14%1.26%20.70%-15.22%9.76%-5.46%35.90%
20172.71%-2.29%0.03%16.58%4.92%2.75%-2.59%-1.32%-3.83%-6.48%14.64%-3.83%20.29%
2016-0.98%11.24%1.39%20.41%-7.26%1.25%14.83%0.56%4.69%-21.02%-12.99%13.10%18.64%
2015-1.59%6.12%7.10%-11.10%3.21%8.96%6.83%-7.41%0.92%10.54%3.72%-3.09%24.01%
2014-0.97%7.13%6.32%9.84%-0.33%5.71%5.14%9.98%2.91%18.37%7.24%-1.77%93.70%
2013-0.27%-4.45%-4.39%-22.36%4.19%1.11%6.22%-1.40%-1.07%-6.38%0.52%0.35%-27.07%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of EW is 41, suggesting that the investment has average results relative to other stocks in terms of risk-adjusted performance. This ranking is determined by the cumulative values of the indicators listed below.


The Risk-Adjusted Performance Rank of EW is 4141
Combined Rank
The Sharpe Ratio Rank of EW is 4343
Sharpe Ratio Rank
The Sortino Ratio Rank of EW is 3737
Sortino Ratio Rank
The Omega Ratio Rank of EW is 4141
Omega Ratio Rank
The Calmar Ratio Rank of EW is 4343
Calmar Ratio Rank
The Martin Ratio Rank of EW is 4242
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Edwards Lifesciences Corporation (EW) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
The chart of Sharpe ratio for EW, currently valued at 0.03, compared to the broader market-4.00-2.000.002.004.000.032.51
The chart of Sortino ratio for EW, currently valued at 0.31, compared to the broader market-4.00-2.000.002.004.000.313.37
The chart of Omega ratio for EW, currently valued at 1.07, compared to the broader market0.501.001.502.001.071.47
The chart of Calmar ratio for EW, currently valued at 0.02, compared to the broader market0.002.004.006.000.023.63
The chart of Martin ratio for EW, currently valued at 0.06, compared to the broader market0.0010.0020.0030.000.0616.15
EW
^GSPC

The current Edwards Lifesciences Corporation Sharpe ratio is 0.03. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Edwards Lifesciences Corporation with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.

Rolling 12-month Sharpe Ratio-1.000.001.002.003.00JuneJulyAugustSeptemberOctoberNovember
0.03
2.48
EW (Edwards Lifesciences Corporation)
Benchmark (^GSPC)

Dividends

Dividend History


Edwards Lifesciences Corporation doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-50.00%-40.00%-30.00%-20.00%-10.00%0.00%JuneJulyAugustSeptemberOctoberNovember
-48.15%
-2.18%
EW (Edwards Lifesciences Corporation)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Edwards Lifesciences Corporation. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Edwards Lifesciences Corporation was 54.32%, occurring on Jul 25, 2024. The portfolio has not yet recovered.

The current Edwards Lifesciences Corporation drawdown is 48.15%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-54.32%Dec 31, 2021644Jul 25, 2024
-50.48%Sep 1, 200043Nov 1, 2000165Jun 29, 2001208
-44.02%Oct 5, 2012299Dec 13, 2013217Oct 24, 2014516
-37.11%Feb 12, 2002112Jul 23, 2002199May 7, 2003311
-36.15%Nov 29, 201978Mar 23, 2020110Aug 27, 2020188

Volatility

Volatility Chart

The current Edwards Lifesciences Corporation volatility is 6.41%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%JuneJulyAugustSeptemberOctoberNovember
6.41%
4.06%
EW (Edwards Lifesciences Corporation)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Edwards Lifesciences Corporation over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Valuation

The Valuation section provides an assessment of the market value of Edwards Lifesciences Corporation compared to its peers in the Medical Devices industry.


PE Ratio
50.0100.0150.0200.0250.0300.025.8
The chart displays the price to earnings (P/E) ratio for EW in comparison to other companies of the Medical Devices industry. Currently, EW has a PE value of 25.8. This PE ratio falls in the average range for the industry.
PEG Ratio
-60.0-40.0-20.00.020.040.060.080.06.1
The chart displays the price to earnings to growth (PEG) ratio for EW in comparison to other companies of the Medical Devices industry. Currently, EW has a PEG value of 6.1. This PEG ratio is much higher than those of other companies of the industry. This might be an indicator of the company being overvalued.

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Edwards Lifesciences Corporation.


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items